

1 **Title page**

2 Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid Cancer

3

4 Running title: Proteomics & RR-PTC

5

6 Author

7 Hanqing Liu ^{1, #}, Jiayi Wang ^{1, #}, Yaoting Sun ^{2, 3, 4, #}, Yan Zhou ^{2, 3, 4, #}, Pingping Hu ^{2, 3, 4}, Lu Li ^{5, 2}, Dan
8 Yang ⁶, Deguang Kong ¹, Zhiliang Xu ¹, Yi Zhu ^{2, 3, 4}, Tiannan Guo ^{2, 3, 4, *}, Chuang Chen ^{1, *}

9

10 Addresses

11 ¹ Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan University
12 at Jiefang Road 238, Wuhan 430060, China.

13 ² School of Medicine, Westlake University, Hangzhou 310024, Zhejiang Province, China.

14 ³ Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine,
15 Hangzhou 310024, Zhejiang Province, China.

16 ⁴ Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou
17 310024, Zhejiang Province, China.

18 ⁵ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310024, China.

19 ⁶ Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University,
20 Chongqing 400010, China.

21

22 # Equal contribution.

23

24 * Correspondence:

25 Prof. Chuang Chen, M.D.,

26 Department of Thyroid and Breast Surgery,

27 Renmin Hospital of Wuhan University,

28 Wuhan University at Jiefang Road 238, Wuhan 430060, RP China.

29 Tel: +86(0)27 88041911; Fax: +86(0)27 88041911, Email: chenc2469@whu.edu.cn.

30

31 Prof. Tianna Guo, Ph.D.,

32 Westlake Laboratory of Life Sciences and Biomedicine,

33 School of Medicine,

34 Westlake University (Yunqi Campus) at No. 18 Shilongshan Rd., Hangzhou 310024, PR China,

35 Tel: +86(0)571 8688 6859; Fax: +86(0)571 8688 6859; Email: guotiannan@westlake.edu.cn.

36

37 **Abstract and keywords**

38 Abstract:

39 Background: Despite the generally favorable prognosis of papillary thyroid cancers (PTCs) following
40 thyroidectomy and potential radioactive iodine (RAI) therapy, approximately one-third of patients
41 experiencing recurrence and metastasis eventually develop resistance to RAI, leading to a poor outcome.
42 However, the mechanisms underlying RAI-refractoriness remain elusive. The present study aimed to
43 assess the molecular and proteomic characteristics of RAI-refractory PTC (RR-PTC) to gain a deeper
44 understanding of this condition.

45 Methods: The medical records at our institution were reviewed for the selection and grouping of RR-
46 PTC patients and RAI-sensitive controls. RR-PTC patients were divided into three subgroups:
47 continuous RAI uptake (ID), loss of uptake at the first I-131 treatment (iDF) and RAI uptake lost
48 gradually (iDG). Proteomic profiling and targeted next-generation sequencing were performed on
49 formalin-fixed paraffin embedded primary lesions. The incidence of gene mutations and fusions was
50 compared across groups. Bioinformatic analysis was subsequently conducted to identify the differentially
51 expressed proteins and enriched pathways. The correlation of protein expression and gene variances was
52 assessed.

53 Results: A total of 48 PTC patients with recurrence and/or metastasis were included. The expression
54 profiles of the RR-PTC and control groups were similar. In the subgroup comparison, enriched pathways
55 related to MAPK and TNF signaling were associated with negative I-131 uptake and tumor tolerance
56 with positive I-131 uptake. The *BRAF*^{V600E} mutation was less common in the ID group, whereas the *TERT*
57 promoter mutation was more common in the iDF group. *NCOA4-RET* fusion was more common in the
58 ID group. In addition, four proteins were dysregulated in *BRAF*-mutated PTCs.

59 Conclusion: The present study constructed the first proteomic profile of RR-PTC. The proteins and
60 pathways identified in the analysis may be promising biomarkers and drug targets. Gene alterations and
61 fusions can aid in the early diagnosis of RR-PTC.

62

63 Keywords: thyroid carcinoma, radioactive iodine, refractoriness, proteomics, NGS, *RET/PTC3*.

64

65

66 1 Introduction

67 Thyroid cancer ranks eighth among female malignancies¹. The incidence of this disease has increased
68 threefold or greater during the past four decades in many countries²⁻⁴. Papillary thyroid cancer (PTC) is
69 the most common histological type and accounts for 70-96% of all thyroid cancers^{4,5}. Most patients with
70 PTC achieve complete remission after undergoing lobectomy or total thyroidectomy and neck dissection.
71 However, approximately half of PTC patients present with aggressive tumor behaviors, such as tumor
72 invasion into perithyroidal tissues, aggressive histology, vascular invasion, multiple lymph node
73 metastases, and distant metastases^{6,7}. These patients have an intermediate or high risk of recurrence and
74 are thus considered or recommended for postsurgical radioactive iodine (RAI) therapy⁸. Unfortunately,
75 one to two-thirds of patients in this subset ultimately develop RAI-refractoriness (RAIR), especially
76 those with a high risk of recurrence^{9,10}. RAI therapy barely improves patient prognosis under these
77 conditions. The 10-year survival rate of patients with RAI-refractory PTC (RR-PTC) has decreased to
78 20-65%, and their life expectancy has substantially decreased^{10,11}.

79 Currently, the diagnosis of RR-PTC depends on an I-131 whole-body scan (WBS) and evidence of
80 regional and/or distant metastatic lesions⁸. Owing to the high affinity of thyroid follicular cells for iodine,
81 radioactive isotopes are concentrated in PTC cells and exert a tumor-killing effect by emitting β -rays. In
82 most cases, two or more I-131 WBSs are required for the final confirmation of RAIR. Given that the
83 routine time interval between two I-131 WBSs is six months¹², the diagnosis of RAIR is made nine to
84 twelve months after the initial surgery. The time lag postpones the start of systemic therapy (e.g. multi-
85 kinase inhibitors, MKIs) and/or local treatments. Early identification of the RAIR can avoid unnecessary
86 RAI therapy and thus improve patient prognosis by shifting to alternative treatments.

87 Many studies have focused on the early diagnosis of RAIR cancer during the past decade. Positron
88 emission tomography (PET) is a valuable tool. Previous studies have shown that the “flip-flop”
89 phenomenon of I-131 WBSs and PET (negative I-131 and positive F-18-FDG uptake) is indicative of the
90 RAIR¹³. In addition to radiological tools, *BRAF*^{V600E} and *TERT* promoter mutations can also contribute
91 to the diagnosis of RAIR. The *BRAF*^{V600E} mutation can impair the expression of the sodium iodide
92 symporter (NIS) and promote malignancy in tumor cells^{14,15}. A previous retrospective study revealed
93 that a combination of *BRAF*^{V600E} and *TERT**p* mutations, which presented in one-fifth of the PTC cohort,
94 strongly predicts RR-PTC at a positive predictive value of 97.4%¹⁶. However, for approximately 80%
95 of patients without the genetic duet, the negative predictive value was only 47.6%. A subsequent study
96 revealed that 52.9% of patients with the genetic duet presented with RAIR¹⁷. Generally, several factors,
97 including high cost and unsatisfactory accuracy, have restricted the use of these diagnostic tools in
98 clinical practice. Currently, the four criteria for RAIR differentiated thyroid cancer (DTC) are still based
99 on the I-131 WBS and additional evidence for recurrence or metastasis⁸. In addition, although the RAIR
100 is related to gene alterations in clinical studies^{18,19}, the mechanism underlying refractoriness is not fully
101 understood. For example, the NIS protein was not necessarily downregulated, as the above article
102 revealed. It can be upregulated and exert a non-pump pro-tumorigenic effect on thyroid cancer cells^{20,21}.

103 Proteins are important participants in tumorigenic processes and dedifferentiation. Mass-based
104 proteomics is a rapidly developing technique that facilitates comprehensive investigations into molecular
105 activities and biological processes involved in cancer initiation and progression. Lots of diagnostic
106 biomarkers and therapeutic targets in clinical practice are based on proteins. Proteomics has been widely
107 used to reveal the cellular activities of thyroid cancer cells since its first appearance^{22,23}. Recently,

108 proteomics has been used in several areas of thyroid cancer research, including discrimination of benign
109 and malignant nodules, subtype identification, and risk stratification^{24,25}. During the past two years, Sun
110 *et al.* constructed a comprehensive thyroid tissue proteomic spectral library and distinguished between
111 follicular adenomas and follicular thyroid carcinomas²⁶. In addition, Shi *et al.* plotted the multi-omic
112 atlas of medullary thyroid carcinoma via the proteomic technique²⁷. The proteomic profile of RR-PTC
113 has not yet been revealed, which may help improve the early diagnosis of RR-PTC in clinical practice
114 and understand the mechanism of RAIR.

115 This study aimed to construct 23-gene panel-based molecular and proteomic profiles of RR-PTC and
116 to identify promising biomarkers related to RAIR, which could aid in early identification and drug target
117 selection.

118

119 2 Results

120 2.1 Patient cohort

121 Based on the inclusion and exclusion criteria in the Patients and Methods section, forty-eight patients
122 with locoregional or distant metastatic PTCs were recruited for our study (Table 1). The average age of
123 all patients was 38.4 ± 12.69 years, and the patients in the RR-PTC group were slightly older than those
124 in the control group ($P = 0.421$). Interestingly, all five patients ≥ 55 years old were in the RR-PTC group.
125 Although females were more common in the control group (72.7% vs. 54.1%, $P = 0.319$), the difference
126 was not significant. In addition, no differences were found in the tumor diagnosis, smoking status or
127 alcohol consumption, body mass index or the incidence of concomitant thyroid diseases between the two
128 groups.

129 The histopathological subtypes of PTC were identically distributed between the two groups. No
130 significant differences were found in terms of tumor size, multifocality or bilateral lesions. The incidence
131 of extrathyroidal extension (ETE) was greater in the RR-PTC group with marginal statistical significance
132 ($P = 0.095$). Owing to differences in age and ETE, T2-4 categories were more common in patients with
133 RR-PTC (91.9% vs. 63.6%, $P = 0.039$). The presence of lymph node metastatic lesion (LNM) was similar
134 in the two groups, but distant metastasis was much more common in the patients with RR-PTC (56.8%
135 vs. 9.1%, $P = 0.006$). Consequently, higher AJCC stages were observed in RR-PTC patients ($P = 0.001$).
136 Compared with patients in the control group, patients in the RR-PTC group received larger doses of I-
137 131 after the initial resection of primary tumors. Notably, all six patients who died were in the refractory
138 group.

139

140 2.2 Molecular profile of PTCs correlated with I-131 resistance

141 A total of 23 genes were sequenced (Sup table S1). Four genes were found to harbor driver mutations
142 (Table 2). The *BRAF*^{V600E} mutation was identified in 25 samples (56%), with no significant difference
143 between the RR-PTC group and the control group (54.3% vs. 60.0%, $P = 1.000$). All six samples with
144 *TERT**p* mutations (17.1% vs. 0%, $P = 0.312$) were in the RR-PTC group. In addition, *RET* and *TP53*

145 mutations were found in one and two patients, respectively. *RAS* mutations, including *HRAS*, *KRAS* and
146 *NRAS*, were not detected in any samples. In addition, four kinds of gene fusions were found, namely,
147 eight samples with *NCOA4-RET*, two with *CCDC6-RET*, three with *ETV6-NTRK3* and one with *STRN-*
148 *ALK*. Fusions were more frequent in the control group (28.6% vs. 40.0%, $P = 0.700$), whereas *RET*-
149 related fusions were almost equally distributed (22.9% vs. 20.0%, $P = 1.000$). However, no significant
150 differences in the expression of these genes were found between the two groups.

151 The forty-five samples were then divided into four subgroups. The *BRAF*^{V600E} mutation was less
152 common in the continuous RAI uptake (ID) group (11.1%, $P < 0.05$), whereas the *TERT**p* mutation was
153 more frequent in the loss of uptake at the first I-131 treatment (iDF) group (33.3%, $P < 0.05$). Notably,
154 *NCOA4-RET* fusion was more common in the ID group (44.4%, $P < 0.05$).

155 The present study further evaluated the associations between gene variants and I-131 uptake. The
156 samples in the ID and RAI-sensitive PTC (Id) groups were categorized as positive for I-131 uptake.
157 *BRAF*^{V600E} mutation was more frequent in the negative I-131 uptake group with statistical significance
158 (69.2% vs. 37.8%, $P = 0.039$). The incidence of *TERT**p* mutations was also greater in this group (19.2%
159 vs. 5.3%, $P = 0.222$). In contrast, fusions were more common in the positive uptake group (23.1% vs.
160 42.1%, $P = 0.206$).

161 The distribution of gene variants with unknown clinical significance was also assessed (Sup table S2).
162 Four variants were subjected to nonparametric tests after those with a frequency < 3 were filtered out.
163 The four mutations were located on *ATM* (c.1236-2A>T), *PTEN* (c.402G>A) and *RET* (c.2071G>A and
164 c.2671T>G). Three variants were more common in the RR-PTC group, except for *PTEN* c.402G>A,
165 although the difference was not statistically significant. In subgroup analysis, the incidence of *PTEN*
166 c.402G>A was greater in the ID group (22.2%, $P < 0.05$). In addition, *PTEN* c.402G>A was associated
167 with positive I-131 uptake with marginal significance (0% vs. 15.8%, $P = 0.068$).

169 2.3 Overview of the proteomic profiling

170 To profile the proteomic characteristics of RR-PTC, we collected 168 tissue slides from 73 patients. A
171 total of 9769 proteins were identified (Sup figure 1A), which indicated the high quality of our data. Since
172 the number of proteins identified in all the samples exceeded the threefold interquartile range (≤ 1614),
173 no sample was excluded from subsequent analysis. The principal component analysis (PCA) plot
174 annotated by batch groups indicates no observable batch effect during data acquisition (Sup figure 1B).
175 Although samples were well resolved by their site, tumor tissues mixed with little difference but negative
176 lymph nodes were clustered (Sup figure 1C). The *R* values of correlation analyses exceeded 0.97 in both
177 intra-batch and inter-batch tests, indicating high technical stability across the data acquisition (Sup figure
178 1D&E). Overall, no observable batch effect was detected (Sup figure 1F).

179 Next, the raw files were converted to an expression matrix. We applied a filtering criterion to select
180 proteins with missing values less than 50%. These 7406 filtered proteins were then subjected to data
181 normalization and outlier substitution (Sup figure 2A-C). After ID conversion, an expression profile
182 encompassing 7394 proteins across 168 samples was compiled (Sup figure 2D). As indicated by the
183 *ESTIMATE* algorithm, the median tumor purity was 76.2% (Sup figure 2E), indicating the reliability of
184 our dataset for further analysis.

185 The global proteomic profiles of the original PTC lesions were subjected to dimensionality reduction
186 to evaluate the clustering of the samples. The area covered by the samples represented similarity within

187 a group. The RAI-sensitive samples were more tightly clustered than the RR-PTC samples (Figure 1A).
188 The overlap of the two groups might be explained by the similarity between tumor tissues and the
189 intrinsic heterogeneity of RR-PTC samples. To minimize potential heterogeneity, we furtherly divided
190 RR-PTCs into three subgroups (iDF, iDG and ID) as described in the patients and tissue selection section.
191 The diversity of the ID group was the lowest among the three subgroups, while the diversity of the RAI
192 uptake lost gradually (iDG) group was the highest (Figure 1B). Interestingly, when labeled with the
193 *BRAF*^{V600E}-mutation status, samples in the two groups were separately clustered (Figure 1C).

194 Subsequently, 107 differentially expressed proteins (DEPs) with P values < 0.05 and absolute fold
195 change (FC) > 1.414 were identified via the multiple linear regression algorithm (Figure 1D). Eighty-
196 nine proteins were upregulated in the RR-PTCs, whereas the remaining eighteen proteins were
197 downregulated. The top upregulated protein in the RR-PTCs was KRT71 (keratin, type II cytoskeletal
198 71, $\log_2FC = 1.422$). Interestingly, the top downregulated protein also belonged to the keratin family
199 (keratin, type I cytoskeletal 16, KRT16, $\log_2FC = -0.955$), which suggested the potential involvement of
200 the cytoskeleton in the progression of RAI. Samples were clustered unsupervisedly based on the 107
201 DEPs and then labeled with clinicopathological features (Figure 1E). The borders of the
202 clinicopathological labels were generally indistinct. However, the thyroid differentiation score (TDS)
203 and extracellular signal-regulated kinase (ERK) score were correlated with the groups to some extent
204 (Figure 1F). The TDS was lower in the RR-PTC group, which could indicate poorer differentiation ($P =$
205 0.288). Conversely, the ERK score was greater in the RR-PTC group ($P = 0.215$). Unfortunately, none
206 of these scores reached statistical significance.

207 Gene set enrichment analysis (GSEA) based on the Reactome database revealed 64 pathways with
208 statistical significance (Sup figure 3A). Twenty-nine pathways with positive normalized enrichment
209 scores (ESs) were upregulated in RR-PTC samples. The pathway with the greatest increase was gamma
210 carboxylation hypusine formation and arylsulfatase activation (nES = 1.687). In addition, Akt
211 phosphorylates targets in the cytosol was also upregulated (nES = 1.552). The remaining 39 pathways
212 were downregulated. Regulation of mRNA stability by proteins that bind Au-rich elements was mostly
213 suppressed for RR-PTCs (nES = -1.960). Notably, *RAS* processing was also downregulated (nES = -
214 1.728). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database was also used for the
215 annotation of pathways closely related to oncogenesis and dedifferentiation (Sup figure 3B). P53
216 signaling was significantly enriched (nES = 1.5440, $P = 0.0136$). Interestingly, the MAPK signaling
217 pathway showed a slight positive correlation with RR-PTCs (nES = 1.2623, $P = 0.1642$). The gene set
218 variation analysis (GSVA) results supported the above results (Sup figure 3C).

219 A previously published study assessed the transcript profiles of RR-PTC via a gene microarray²⁸. The
220 DEPs identified in the present study were assessed via this profile to determine whether they were robust
221 in another cohort. Ninety-nine of the 107 DEPs were identified in this cohort, and only three of them
222 were dysregulated (Sup figure 3D). *BET1* and *C11orf96* were downregulated in the RR-PTC group
223 (*BET1* median: 6.534 vs. 6.105, $P = 0.032$; *C11orf96* median: 7.338 vs. 7.028, $P = 0.032$). The expression
224 of *SLC4A9* was greater in the RR-PTC group (median: 5.216 vs. 5.392, $P = 0.045$). Notably, the
225 regulation direction of *BET1* and *SLC4A9* was consistent with the results of the present study, whereas
226 *C11orf96* was oppositely expressed in the two analyses. GSVA based on the Reactome and KEGG
227 databases revealed two differentially downregulated pathways (N-glycan antennae elongation and GAB1
228 signalosome), none of which were enriched in our study (Sup figure 3E&F).

229 To assess the spectral change in RR-PTC, the Id, ID and iDF subgroups were defined as having low,
230 intermediate and high severity, respectively. A total of 403 proteins with significance difference in

231 analysis of variance were divided into six clusters (Sup figure 4). In two clusters, 160 proteins were
232 monotonically regulated (Sup figure 5A). Collagen biosynthesis and modifying enzymes were
233 significantly enriched in Metascape (Sup figure 5B). In addition, regulation of protein
234 autophosphorylation and regulation of extrinsic apoptotic signaling pathway were also associated with
235 the severity of RR-PTC. The results were supported by the ingenuity pathway analysis (IPA) database
236 (Sup figure 5C).

237

238 2.4 Proteomic biomarkers and pathways associated with I-131 uptake

239 For analysis of proteomic biomarkers and the underlying mechanisms for the loss of I-131 uptake in
240 PTC, two subgroups, ID and iDF, were included in the subsequent analysis of this section. The ability of
241 these two groups to take up I-131 was completely different at the first radiotherapy. The demographic
242 and clinicopathologic characteristics of the two groups were roughly comparable (Sup table S3). No
243 significant differences were observed in histopathological features, tumor staging or risk stratification.
244 Interestingly, four patients in the iDF group drank alcohol and/or smoked, while no individual in the ID
245 group reported these behaviors ($P = 0.033$). In addition, the patients in the iDF group had greater weights
246 than their counterparts ($P = 0.010$). Since the diagnosis of RR-PTC in the ID group required multiple
247 rounds of I-131 treatment, the cumulative dose of I-131 was inevitably greater than that in the iDF group
248 ($P = 0.001$).

249 Although the ID and iDF groups overlapped with each other to some extent, a total of 145 DEPs were
250 identified with P values < 0.05 and absolute FC > 1.414 (Figure 2A&B). Ninety-five proteins were
251 upregulated in the ID group, whereas the remaining 50 proteins were highly expressed in the iDF group.
252 The 145 DEPs could barely separate the two groups. The TDS was greater in the ID group, whereas the
253 ERK score was lower. However, none of these scores reached statistical significance (Figure 2C&D).

254 Pathway enrichment analysis was then conducted. Only seven pathways in the KEGG database were
255 significantly enriched. Among the seven pathways, glutathione metabolism and Notch signaling were
256 enriched in the ID group whereas TGF-beta signaling and ECM receptor interaction were enriched in the
257 iDF group (Figure 2E). Fifty-one pathways in the Reactome database were significantly enriched. The
258 top enriched pathway was “activated TAK1 mediates P38 MAPK activation” with an nES of 1.9182
259 (Figure 2F). In addition, several MAPK-related pathways, including ERK/MAPK targets and prolonged
260 ERK activation events, were correlated with positive I-131 uptake. In addition, TNF signaling and
261 glutathione conjugation were associated with positive I-131 uptake.

262 The results of pathway enrichment were then assessed via GSEA. Sixty-three pathways were
263 significantly enriched and 18 of these pathways overlapped with the GSEA results (Figure 3A). After the
264 associations between pathways and tumor progression were evaluated, sixteen pathways were found to
265 play roles in the loss of I-131 uptake in PTC, eleven of which overlapped with the GSEA results (Figure
266 3B). Six pathways were closely related to MAPK signaling. Three pathways are associated with
267 transforming growth factor- β activated kinase 1 (TAK1) signaling. In addition, one pathway was
268 correlated with both MAPK and TAK1 signaling. The other six pathways involved glutathione
269 metabolism, TNF signaling and MET proto-oncogene (MET) signaling. The expression of proteins
270 involved in these thirteen pathways was compared between the RAI-positive and RAI-negative groups.
271 Proteins with an absolute FC > 1.2 were displayed (Figure 3C).

272 The results of our proteomic profile were validated with a transcriptomic profile of RR-PTCs

273 (GSE151179). The samples in GSE151179 were categorized as ID or iD based on their I-131 uptake.
274 The iD group was not subdivided into iDF or iDG since the information was not provided. A linear
275 regression algorithm identified three common differentially expressed genes (DEGs) (Sup figure 6A).
276 However, the regulatory direction was completely different. In the proteomic profile, MYH7 was up-
277 regulated, whereas in the transcriptomic profile, its expression was greater in the iD group. S100B and
278 UXT also exhibited inverse changes in the two profiles. Only MYH7 significantly differed according to
279 the nonparametric test ($P = 0.035$). GSEA revealed five common pathways (Sup figure 6B), and the
280 direction of the change in expression was consistent between the two profiles. Notably, three TAK1-
281 associated pathways were significantly enriched. All genes involved in the 16 selected pathways and
282 these five common pathways were tested. Only three genes were differentially expressed between the
283 two groups. PI4K2B and PIK3R4 participate in the synthesis of PIPs at the early endosome membrane,
284 and CEACAM8 is involved in fibronectin matrix formation (Sup figure 6C).
285 Immune analysis based on the ssGSEA matrix revealed an abundance of memory B cell and a deficiency
286 of macrophage and immature T cell in the ID samples (Sup figure 7A). Notably, eosinophils were more
287 abundant in RAI-sensitive samples compared to RR-PTCs. However, immunohistochemistry results did
288 not show any statistically significant differences (Sup figure 7B).
289

290 2.5 Proteomic biomarkers and pathways for different responses to positive I-131 uptake

291 The data of twenty-one patients in the ID group and the Id group (or control group) were compared to
292 determine the potential mechanisms underlying the different responses to positive I-131 uptake in PTC
293 patients. The baseline characteristics of the two groups were compared (Sup table S4). No significant
294 differences in demographic or tumor features were found, except for a greater incidence of ETE in the
295 ID group ($P = 0.035$). More distant metastases were found in the ID group (80% vs. 9.1%, $P = 0.002$),
296 and consequently, the disease stages were greater ($P < 0.001$). According to the criteria of the ID group,
297 the cumulative I-131 dose was inevitably greater ($P < 0.001$).

298 Similar to the previous comparison, the two groups could be distinctly separated from each other (Figure
299 4A). Twenty-one samples were roughly divided into two groups with 125 DEPs identified via the
300 multiple linear regression algorithm (Figure 4B&D). No significant differences were found in the TDS,
301 ERK score, T cell infiltration score (TIS), immune infiltration score (IIS) or immune cytolytic activity
302 score (CYT) (Figure 4C).

303 GSEA revealed twelve enriched pathways based on KEGG annotations. The p53 signaling pathway (P
304 = 0.0498) and mTOR signaling pathway ($P = 0.0346$) were both promoted in the RAI-resistant samples
305 (Figure 4E). Interestingly, inositol phosphate (IP) metabolism was also activated in the ID group ($P =$
306 0.0190). No significant difference was revealed in the MAPK signaling pathway. Forty-five pathways
307 were significantly enriched according to the Reactome annotation file. TP53-related pathways, including
308 regulation of TP53 through association with co-factors ($P = 0.0260$) and methylation ($P = 0.0463$), were
309 increased in ID samples (Figure 4F). TNF signaling ($P = 0.0188$) and its participant TNFR1-induced NF-
310 kappa-B signaling pathway ($P = 0.0021$) were both associated with RAI uptake and resistance. In
311 addition, the pathway “activated TAK1 mediates p38 MAPK activation” was closely related to RAI-
312 resistance ($P < 0.0001$). An increase in IP metabolism was also detected ($P = 0.0081$).

313 GSEA based on the Reactome annotation file was conducted to verify the previous results. A total of 49
314 pathways were enriched with significant differences, eleven of which overlapped with previous results

315 (Figure 3D). After the search and selection, four clusters comprising thirteen pathways were pooled for
316 subsequent analysis (Figure 3E). Eight of the thirteen pathways were also dysregulated according to
317 GSEA. A total of 39 proteins involved in TNF signaling, TAKI-related pathways, plasma lipoprotein
318 remodeling and IP-related pathways were identified with an absolute FC > 1.2 (Figure 3F).

319 The expression levels in the transcriptomic profiles of the ID and Id groups were then compared for
320 validation. Only PGS1 was downregulated in the ID group (median: 6.080 vs. 6.456, $P = 0.012$; Sup
321 figure 6D), which was consistent with the proteomic data. According to the pathway analysis, only GAB1
322 signalosome was significantly decreased in the ID group ($P = 0.012$, Sup figure 6E). However, none of
323 the genes in the GAB1 signalosome were differentially expressed between the two groups. Among those
324 involved in the above thirteen pathways, three genes (MAPKAPK2, NFKB1 and PLKHA6) were
325 downregulated in the ID group, in contrast to the expression pattern observed in our proteomic profile
326 (Sup figure 6F).

327

328 2.6 Association of gene variance and protein expression

329 The 7394 proteins were divided into 21 modules via weighted correlation network analysis (WGCNA)
330 (Figure 5A&B). *BRAF* mutation was significantly correlated with seven gene modules, among which the
331 blue module had the highest absolute correlation coefficient (CC) ($CC = 0.61$, $P = 8.4e-6$). The most
332 prominent module associated with *TERTp* mutations was pink ($CC = -0.45$, $P = 1.9e-3$). The green-
333 yellow module was closely related to the gene fusions ($CC = 0.42$, $P = 3.7e-3$) and the *NCOA4-RET*
334 fusion ($CC = 0.32$, $P = 0.03$). For other gene variants of unknown significance, *ATM* c.1236-2A>T was
335 related to the green module ($CC = 0.41$, $P = 5.0e-3$). In addition, *RET* c.2671T>G was closely associated
336 with the yellow module ($CC = 0.50$, $P = 4.5e-4$).

337 Three machine learning algorithms (LASSO, RF and SVM-RFE) were used to select biomarker proteins
338 from the most correlated modules of each gene mutation and fusion. Since other gene mutations were
339 generally rare (< 10%) in the present study, samples with *BRAF* mutation, *TERTp* mutation, gene fusion
340 and *NCOA4-RET* fusion were retained for subsequent analysis. A total of 28, 32 and 39 proteins were
341 used for model construction of *BRAF* mutations via the least absolute shrinkage and selection operator
342 (LASSO) regression, random forest (RF), and support vector machine-recursive feature elimination
343 (SVM-RFE) algorithms, respectively, and four of these proteins were common biomarkers (Figure 5C).
344 In addition, only PTC1 and AHCYL2 were revealed to be common biomarkers for gene fusions.
345 According to the receiver operating characteristic (ROC) curves of The Cancer Genome Atlas Thyroid
346 Cancer (TCGA-THCA) dataset, the areas under the curve (AUCs) of three genes exceeded 0.9 (Figure
347 5D). PTPRE had the highest accuracy (AUC = 0.93), followed by TMEM43 (AUC = 0.92) and FN1
348 (AUC = 0.91). According to the merged Gene Expression Omnibus (GEO) profile, the most accurate
349 gene was TMEM43 (AUC = 0.80), followed by FN1 (AUC = 0.73) and SUS2 (AUC = 0.69).
350 Interestingly, PTPRE did not significantly differ. The AUCs of AHCYL2 for gene fusions in TCGA-
351 THCA and merged GEO cohorts were 0.65 and 0.68, respectively. Disease free survival analysis revealed
352 that dysregulation of FN1 (HR = 2, $P = 0.026$) and AHCYL2 (HR = 0.53, $P = 0.038$) was associated with
353 poor prognosis in patients with thyroid cancer (Sup figure 8).

354 To explore the potential biomarkers and pathways in case of *BRAF* mutation and wild-type *TERTp*, only
355 19 *BRAF*-mutated and *TERTp*-unmutated samples were analyzed. A total of 184 proteins were
356 significantly different between the RAIR-refractory and RAIR-sensitive groups (Sup figure 9A&B).

357 Metascape revealed that several pathways related to the immune response, including T cell activation,
358 regulation of lymphocyte activation and phagocytosis, were enriched with statistical significance (Sup
359 figure 9C). IPA results also supported these findings (Sup figure 9D). Granzyme A signaling was
360 downregulated in *BRAF*-wild-type samples, whereas neutrophil degranulation, B cell development and
361 phagosome formation were upregulated in *BRAF*-mutated *TERTp*-unmutated samples.
362

363 **3 Discussion**

364 To our knowledge, the present study is the first to construct a proteomic profile of RR-PTC on primary
365 lesions. We evaluated the differences in the expression of genes in the RAI-refractory and RAI-sensitive
366 samples. Three genes were potential biomarkers for RR-PTC. To minimize the intrinsic heterogeneity
367 due to different criteria, we subdivided RR-PTC primary lesions based on the response to radiotherapy
368 and the presence of I-131 uptake. Proteins and potential pathways associated with these two tumor
369 behaviors were evaluated. MAPK signaling was the most commonly involved pathway. TGF-beta and
370 TAK1 signaling was revealed to be associated with the loss of I-131 uptake. In contrast, tumor necrosis
371 factor (TNF) signaling might affect cancer cell death in positive foci. Targeted deep sequencing revealed
372 that wild-type *BRAF* and *TERTp* mutation were associated with the ID and iDF phenotypes, respectively.
373 *NCOA4-RET* fusion was more frequent in the ID group. With respect to protein expression and gene
374 variance, four proteins were associated with *BRAF*^{V600E} mutation.

375 Many previous studies have investigated the dedifferentiation mechanism and redifferentiation targets
376 of RR-PTC. NIS is the most important transporter of iodide and is highly expressed in thyroid epithelium
377 ²⁹. Previously, researchers hypothesized that the downregulation of NIS in primary tumors contributed to
378 the loss of RAI uptake in metastatic RR-DTC lesions ³⁰. This hypothesis was soon challenged by the
379 intracellular overexpression of NIS in ~70% of thyroid cancer samples ²¹. In 2018, Feng *et al.* reported
380 that increased intracellular NIS could exert a non-pump pro-tumorigenic effect ²⁰. The relationship
381 between NIS expression and the RAIR has yet to be determined ^{31,32}. Owing to the methodological
382 limitation of proteomics, we failed to quantify NIS protein expression. However, seven molecules
383 indicating thyroid differentiation, including PAX8, TG and TPO, were identified. Although the TDS
384 tended to increase in the RR-PTC samples, the difference did not reach statistical significance.
385 Consequently, our results do not fully support that thyroid-specific proteins in primary lesions could be
386 used as diagnostic biomarkers for RR-PTC.

387 The associations between thyroid cancer and gene variants have been widely discussed. The pathway
388 most likely related to dedifferentiation and RAI refractoriness was MAPK signaling ³³. MAPK signaling
389 regulates cell proliferation, dedifferentiation and death. *BRAF* is an essential kinase in the cascade. The
390 *BRAF*^{V600E} mutation has been reported to be associated with aggressive tumor behavior and poor
391 prognosis ^{34,35}. Recent studies have revealed a strong correlation between *BRAF*^{V600E} mutation and
392 negative iodine uptake ^{16,28}, which was confirmed by a meta-analysis ³⁶. The overall prevalence of *BRAF*
393 mutation was ~55% in our study, but ID samples were less likely to harbor *BRAF* mutation (~10%) than
394 other subgroups. Given that *BRAF* mutation can impair the expression of the NIS protein ³⁷, recurrent or
395 metastatic lesions without *BRAF* mutation are prone to be positive in I-131 WBSs. Interestingly, a more
396 recent study by Mu *et al.* revealed a lower rate of *BRAF* mutation in the “continuously RAI-avid but
397 RAI-refractory” group (~14%) than in the partial and gradual RAI-refractory groups ³⁸. Although few

398 studies have subdivided RR-PTC based on different criteria, we could hypothesize that ID tumors have
399 distinct molecular features and tumorigenic mechanisms. However, it is difficult to explain the high
400 prevalence of *BRAF* mutation in the Id group in our study, which was not consistent with many previously
401 published articles^{31,38,39}. Some studies have reported no significant correlation between *BRAF* status and
402 RAI uptake^{40,41}. It was assumed that clinical pathways in different countries/regions and patient selection
403 protocols contributed to the diverse observations to some extent³⁵.

404 In addition, *TERTp* mutation is a promising predictive factor for the RAIR. The prevalence of this
405 mutation was lower than that of the *BRAF* mutation, but patients harboring *TERTp* mutations had poorer
406 prognoses and greater mortality⁴². Liu *et al.* reported that the genetic duet of *BRAF* and *TERTp* mutations
407 robustly predicted the loss of RAI avidity in PTCs with a high positive predictive value (97.4%)¹⁶.
408 However, the negative predictive value was lower than 50%, which limits its utility in clinical practice.
409 Subsequent studies have shown similar but somewhat different results¹⁷. The genetic duet could predict
410 RAIR with a positive predictive value barely higher than 50%. A recent study from Shanghai revealed
411 that *TERT* accelerated *BRAF*-mutated thyroid cancer dedifferentiation and progression by regulating
412 ribosome biogenesis⁴³. Our study also revealed a greater rate of *TERTp* mutation in the RR-PTC group.
413 Interestingly, *TERTp* mutation was significantly more frequent in iDF samples, indicating its strong
414 association with the loss of RAI uptake. This observation was in accordance with a previously published
415 article³⁸. Since all six *TERTp*-mutated samples harbored the *BRAF*^{V600E} mutation, we did not test the
416 combined efficacy of the two mutations.

417 Of interest, our study revealed a significantly greater incidence of *NCOA4-RET* (*PTC3-RET*) fusion in
418 the ID group. This phenomenon was also observed in two studies. An Italian study revealed that fusion
419 genes (especially *RET-PTC*) were more common in ID (39%) than in iD (16%) and Id (13%) patients (P
420 = 0.075)²⁸. Mu's study revealed that the incidence of *RET*-fusions in the ID subgroup (~40%) was greater
421 than that in other RR-DTC subgroups and the Id group³⁸. However, statistical significance was not
422 reached in the above two studies. A subsequent study from Mu's institution revealed that fusion
423 oncogenes in pediatric DTCs were associated with RAI-refractoriness ($P = 0.017$)⁴⁴. But *RET*-fusions
424 were not analyzed separately. The radioactive isotope is concentrated in thyroid epithelium-derived
425 tumor cells and exerts tumor-killing effect by emitting β -rays. Considering that *RET* rearrangements can
426 activate its kinase and inhibit apoptosis via the MAPK and PI3K signaling pathways^{45,46}, the apoptosis
427 triggered by radioisotope-induced DNA damage could also be impaired by *RET* alterations, especially
428 the *NCOA4-RET* fusion. The potential causal relationship between *RET* fusion and the ID phenotype has
429 not been verified in cell or animal experiments. Recent clinical studies have shown that the *RET* fusion-
430 directed therapy can restore RAI avidity in patients with RR-PTC^{47,48}.

431 The accuracy of gene mutations and fusions are helpful but not satisfactory. Proteomic analysis was
432 conducted to identify promising biomarkers related to the RAIR. Although the expression differences
433 between phenotypes were generally not obvious, some signaling pathways were significantly enriched.
434 In the comparison of the RAI-sensitive and RAI-refractory groups, P53 signaling was the pathway most
435 likely associated with the loss of iodine uptake. Although some scholars have suggested that *TP53*-
436 mutated follicular adenomas are precursors for the dedifferentiation of anaplastic thyroid cancer⁴⁹, few
437 studies have investigated the correlation between the RAIR and mutations in P53 signaling. At that time,
438 we assumed that the heterogeneity in RR-PTC reduced the power of the test. In the subsequent
439 comparisons of subgroups (ID vs. iDF and ID vs. Id), enriched pathways clustered into several major
440 pathways, including the MAPK signaling and TNF signaling pathways. The MAPK pathway is strongly
441 related to thyroid cancer behaviors, and *BRAF* mutation impairs the expression of the NIS protein by

442 deacetylating its gene promoter histones³⁷. MAPK inhibitors and histone deacetylase inhibitors can
443 restore iodine uptake and re-differentiate PTC cells^{50,51}. Interestingly, our study revealed that TAK1-
444 associated pathways were also correlated with that RAIR. A recent study suggested that silencing TAK1
445 inhibited the proliferation and migration of thyroid cancer cells via that suppression of p38 MAPK
446 signaling⁵². We hypothesize that TAK1 is a novel potential molecular target of RAIR. The TNF signaling
447 is another pathway of interest. TNF is an important cytokine that triggers inflammation. A retrospective
448 study by Gheorghe *et al.* suggested that TNF- α might exert different antitumor effects in response to RAI
449 therapy depending on the patient's immune profile⁵³. The activation of TNF signaling might restore I-
450 131 uptake and promote redifferentiation in thyroid cancer cells. Unfortunately, most proteins involved
451 in these pathways did not significantly differ.

452 Most of the molecules identified in the article were not the main regulators of their pathways. However,
453 these three proteins warrant further discussion. There are few reports of S100B in thyroid cancer, but its
454 high expression promotes cancer metastasis via interaction with P53 signaling in other glandular
455 epithelium-derived carcinomas⁵⁴. NFKB1 belongs to the well-known NF- κ B signaling, which is closely
456 related to cancer initiation and progression. A functional polymorphism in its promoter increases the risk
457 of PTC⁵⁵. In addition, FN1 overexpression was found in aggressive thyroid cancer and promoted its
458 migration and invasion⁵⁶. The expression of this molecule was greater in *BRAF*-mutated PTCs and was
459 indicative of poor prognosis⁵⁷. These proteins are associated with aggressive cancer behaviors and could
460 be promising biomarkers for RR-PTC.

461 The current study did not focus on the iDG group because of its high intrinsic heterogeneity, but one
462 hypothesis could help explain the process of loss of I-131 uptake in this group. The original tumor may
463 comprise heterogeneous cancer cells with different tolerances to I-131 treatment. I-131 exerted a
464 selective effect on cells, and those with greater tolerance survived, which ultimately results in the
465 formation of negative uptake foci on I-131 WBSs.

466 Several previous studies have plotted the molecular and omic atlas of RR-DTC (Sup table S6). Sabra
467 and Shobab independently constructed the genomic landscape for RR-DTC^{58,59}. Mutations in the MAPK
468 signaling pathway accounted for ~50% of oncogenic drivers, which was similar with our results. In 2020,
469 Colombo *et al.* constructed molecular and gene/miRNA profiles for RR-PTC²⁸. *BRAF* mutation was
470 more frequent in the RAI-negative RR-PTC group. Although PTCs were clearly distinguished from
471 normal thyroid tissues, no distinct expression patterns were found between RAI-refractory and RAI-
472 sensitive PTCs. In general, our results were consistent with those of Colombo's study. A distinguishable
473 feature for RAIR was not found based on either the mRNA/miRNA or protein profile, regardless of
474 subclassification. The insufficient sample size may partly explain this phenomenon. One hypothesis is
475 that the RAIR occurs during recurrence and metastasis. The hypothesis, however, is not convincing in
476 the presence of some RAI negative lesions at the first I-131 treatment. Another competing hypothesis is
477 that the underlying mechanisms of the RAIR are trivial and are covered by the heterogeneity of other
478 tumor behaviors. More homogenous samples and proper subclassification are needed to eliminate
479 confounding effects and uncover the underlying mechanisms involved. Two precursor studies provided
480 novel insights into the proteomic expression of RR-PTC but were limited by small sample sizes and the
481 lack of primary tumors^{60,61}.

482 The current study has several shortcomings. First, although the medical records of more than ten
483 thousand patients were reviewed thoroughly by independent researchers, the intrinsic nature of this
484 single-center, retrospective study and the relatively small sample size limit the generalizability of our
485 conclusions. In addition, the lack of Benjamini-Hochberg correction for differential expression analysis

486 undermined the reliability of the results. In addition, due to the lack of previous proteomic profiles,
487 potential protein biomarkers were tested with several external transcriptomic profiles. The consistency
488 of expression across mRNAs and corresponding proteins is debatable ²⁷. Moreover, FTC samples and
489 metastatic lesions were excluded from the present study because of the small sample size and potential
490 histopathological heterogeneity. The potential biomarkers and mechanisms were not verified with *in vivo*
491 experiments. The above observations of our study could be confirmed with multicenter large-sample
492 proteomic profiling. Cell and animal experiments could help verify our results.

493 In conclusion, a proteomic profile based on RR-PTC primary lesions was constructed for the first time
494 in the present study. Our current work improves the molecular and biological understanding of RR-PTC,
495 which could enlighten future preclinical and clinical studies toward molecule-guided treatment. The
496 dataset created in this study could serve as an important resource for further investigations of RR-PTC
497 biology and therapeutic targets.

498

499 **4 Patients and Methods**

500 4.1 Study design and ethics approval

501 This retrospective, case-control study was conducted at Renmin Hospital of Wuhan University. The
502 Institutional Ethical Committee of the hospital reviewed and approved the study design (No.
503 WDRY2021-K032). The requirement for obtaining informed consent from the involved patients was
504 waived due to the retrospective nature of the study. The study was conducted in accordance with the
505 Declaration of Helsinki ⁶². The study was performed in accordance with the STROBE checklist for case-
506 control study (version 4).

507

508 4.2 Patient and tissue selection

509 The medical records of patients who were diagnosed with thyroid cancer at our tertiary center from Jan.
510 1st, 2016 to Dec. 30th, 2022 were reviewed (Figure 6A). Patient demographic and clinicopathological
511 characteristics, laboratory test results and radiological results were collected by two researchers and
512 independently evaluated. During the initial screening, patients who a) had incomplete medical records
513 and b) did not undergo I-131 WBS were excluded. In the second round of assessment, histopathological
514 data and radiological images, including chest computed tomography (CT), cervical magnetic resonance
515 imaging (MRI), whole-body bone scanning and positron emission tomography (PET), were used to
516 evaluate local and distant metastasis at the first admission for surgery. Patients without cervical or distant
517 metastasis at diagnosis were excluded from the subsequent evaluation. Patients with RAI uptake limited
518 to thyroid bed and disease remission were also excluded. In the final assessment, RAI uptake was
519 determined by I-131 WBSs or I-131 single photon emission computerized tomography (SPECT). A total
520 of 73 patients were identified to have locoregional or distant metastasis, which was confirmed by
521 radiological, cytopathological or histopathological solid evidence. Patients with primary lesions not
522 resected in our center or other histopathological types other than PTC were also excluded from further

523 statistical analysis. Finally, forty-eight PTC patients with locoregional and/or distant metastasis were
524 included in this study and their primary tumor samples (one sample from each patient) were used for
525 subsequent analysis.

526 The included patients were then divided into two groups based on their response to RAI treatment: RAI-
527 sensitive (RAI uptake positive and disease remission, Id) and RAI-refractory (disease persistence, Figure
528 6B). RAI refractoriness was identified in accordance with the 2015 American Thyroid Association (ATA)
529 guideline⁸. Briefly, patients with metastatic lesions that a) did not ever concentrate RAI, b) lost the ability
530 to concentrate RAI after previous evidence of RAI avidity, and c) concentrated in some lesions but not
531 in others were considered to have negative RAI uptake. Individuals with d) metastatic disease despite a
532 significant concentration of RAI were defined as having positive uptake. Owing to the potential
533 heterogeneity of RR-PTC, patients in the RAI-refractory group were further categorized into three
534 subgroups: a) negative RAI uptake at the first RAI treatment with disease persistence (iDF), b) RAI
535 uptake lost gradually after previous RAI treatments with disease persistence (iDG), and c) positive RAI
536 uptake but with disease persistence (ID). Tumor stage and the risk of recurrence were stratified using the
537 American Joint Committee on Cancer (AJCC) staging system and the 2015 ATA guideline^{8,63}.

538 Resected primary and metastatic lesions were preserved in formalin-fixed paraffin-embedded (FFPE)
539 tissue blocks at room temperature. A total of 168 FFPE samples were collected from the above 73 patients
540 (Figure 6C). The tissue types included primary tumors, synchronous cervical LNM, LNM after I-131
541 treatment, negative lymph nodes, and regional and distant metastatic lesions. Hematoxylin and eosin-
542 stained slides from all samples were reviewed by two independent pathologists with expertise in thyroid
543 pathology. The tissue blocks with the highest tumor purity in each patient were selected for subsequent
544 analysis. The borderlines of the tumor and adjacent tissues were carefully marked by expert pathologists.
545

546 4.3 Proteomic data acquisition and preprocessing

547 The FFPE samples were prepared for subsequent proteomic analysis as described previously^{26,64}. The
548 samples were allocated into ten batches. The tissues were subjected to a series of manipulations,
549 including dewaxing, rehydration and lysis, for peptide extraction and digestion via pressure cycling
550 technology (PCT). Peptides were then quantified via a liquid chromatography (LC) system coupled with
551 a trapped ion mobility spectrometry mass spectrometer (MS). Data-independent acquisition (DIA) files
552 were acquired and then analyzed against a thyroid tissue specific spectral library²⁶ using DIA-NN (v1.8.1)
553⁶⁵. Correlation analysis was conducted to assess the inter-batch and intra-batch stability of data
554 acquisition. The profile was then processed for protein filtration, imputation and ID conversion. A
555 detailed description of proteomic data acquisition, quality control and preprocessing can be found in the
556 supplementary methods.

557

558 4.4 Targeted next-generation sequencing (TNGS)

559 The primary lesions from 48 patients with PTC were subjected to molecular profiling via TNGS. The
560 protocol was performed as described previously⁶⁶. Briefly, DNA was extracted from FFPE tissue
561 sections using the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany) following the manufacturer's

562 instructions. After amplification of targeted DNA fragments and removal of primers, the products were
563 purified using an Ion AmpliSeq Library Kit (Thermo Fisher Scientific, USA). The concentrations of
564 samples were quantitated by a NanoDrop system (Thermo Fisher Scientific, USA). The quality of the
565 purified DNA was evaluated by 1% agarose gel electrophoresis. Severe degradation was detected in three
566 samples, which were excluded from further analysis.

567 The remaining 45 library products were sequenced via 150 bp paired-end runs on the NextSeq 500
568 platform (Illumina, Inc., USA). The medians of sequencing depth and coverage were 5136× and 98.7%,
569 respectively. Sequencing data were aligned to a reference human genome dataset (hg19/GRCh37).
570 Subsequently, read mapping, quality control, variant calling and genotyping were performed following
571 the protocols of the OncoAim® Thyroid Cancer Multigene Assay Kit (Singlera Genomics, Inc., China).
572 Mutations and fusions were evaluated for 23 genes (Sup table S1). The minimum confidence threshold
573 for variant allele frequency was 5%. The ENSEMBL Variant Effect Predictor (v90) was used for variant
574 functional annotation. In addition, the gene variants were searched against the ClinVar database
575 (v2020006) ⁶⁷. Somatic gene variants were categorized for clinical significance based on the Catalogue
576 Of Somatic Mutations In Cancer database (COSMIC, v97) ⁶⁸.

577

578 4.5 Bioinformatic analysis

579 DEPs were identified using a multiple linear regression algorithm and analysis of variance (ANOVA).
580 Differential expression analysis was conducted using the *limma* R package. Proteins with an absolute
581 FC > 1.414 and a *P* value < 0.05 were defined as DEPs. The dimension of the profile was reduced and
582 visualized using the PCA algorithm. ANOVA was used to identify proteins correlated with the severity
583 of RR-PTC. Proteins with statistical significance were clustered using the *mfuzz* R package. Proteins in
584 monotonically regulated clusters were regarded as DEPs.

585 Pathway enrichment analysis and gene ontology (GO) were conducted using four tools. GSEA was
586 conducted using GSEA software to evaluate potential pathways and molecular mechanisms. For GSVA,
587 ESs were calculated with the *GSEA* R package. Predefined gene sets were downloaded from the
588 Reactome and KEGG databases. The top enriched GO processes were identified via the Metascape web-
589 based platform. Another network tool, IPA, identifies most significantly relevant pathways with the
590 overall activation or inhibition states based on DEPs.

591 Immune infiltration analysis was performed via the *CIBERSORTx*, *ESTIMATE* and *single sample GSEA*
592 (*ssGSEA*) algorithms. Several scores, including the TDS, ERK score and CYT, were calculated based on
593 the normalized protein profile. TIS and IIS were calculated using the *Z* score-standardized ssGSEA
594 matrix. *BRAF-RAS* score (BRS) was not calculated since no *RAS*-mutated samples were identified.

595 WGCNA was performed to cluster genes with high correlation and assess the correlation between
596 protein modules and gene alterations. Proteins in the modules that were highly associated with gene
597 mutations or fusions were selected. Least absolute shrinkage and selection operator (LASSO) regression,
598 random forest (RF), and support vector machine-recursive feature elimination (SVM-RFE) were used to
599 identify biomarker proteins based on selected proteins.

600 Several external datasets were used for the validation of our results (Sup Table S7). GSE151179 from
601 the GEO database included 52 samples derived from radioiodine-refractory and radioiodine-avid PTC
602 patients. This dataset was used to verify the results related to RAI refractoriness. The associations
603 between gene alterations and protein expression were assessed with the THCA (thyroid cancer) program

604 from TCGA and four additional datasets from the GEO database. The predictive performance of the
605 genes in the external datasets was evaluated with ROC curves.

606 A detailed description of the bioinformatic analysis and references to methodological articles can be
607 found in the supplementary methods.

608

609 4.6 Statistical analysis

610 Quantitative variables were displayed as the means \pm standard deviations or medians \pm quartiles,
611 whereas qualitative variables were presented as numbers and ratios. The significant differences in the
612 quantitative variables were determined via two-tailed independent *t* test or Mann-Whitney *U* test, as
613 appropriate. The *chi*-square test was used to evaluate the differences in the distributions of qualitative
614 variables. When multiple groups were present, the *z* test with a Bonferroni correction was used to assess
615 the intergroup difference in every group. Statistical analysis was conducted using SPSS software (IBM,
616 US, v26).

617

618 **Abbreviations**

619 ANOVA, analysis of variance; ATA, American Thyroid Association; AUC, area under the curve (of ROC);
620 *BRAF*, B-Raf proto-oncogene, serine/threonine kinase; BRS, *BRAF-RAS* score; CC, correlation
621 coefficient; COSMIC, the Catalogue Of Somatic Mutations In Cancer; CT, computed tomography; CYT,
622 immune cytolytic activity score; DEG, differentially expressed gene; DEP, differentially expressed
623 protein; DIA, data-independent acquisition; DTC, differentiated thyroid cancer; ECP, eosinophil cationic
624 protein; ES, enrichment score; ERK, extracellular signal-regulated kinase; ETE, extrathyroidal extension;
625 FC, fold change; FFPE, formalin-fixed paraffin-embedded; F-18-FDG, 2-[¹⁸F]fluoro-2-deoxy-D-glucose;
626 GEO, the Gene Expression Omnibus database; GO, gene ontology; GS, gene significance; GSEA, gene
627 set enrichment analysis; GSVA, gene set variation analysis; HR, hazard ratio; ID, positive RAI uptake
628 and disease persistence; Id, RAI uptake positive and disease remission; iDF, negative RAI uptake at the
629 first time of RAI treatment with disease persistence; iDG, RAI uptake lost gradually after previous RAI
630 treatments with disease persistence; IIS, immune infiltration score; IP, inositol phosphate; IPA, ingenuine
631 pathway analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; KNN, K-nearest neighbor;
632 LASSO, least absolute shrinkage and selection operator; LC, liquid chromatography; LNM, lymph node
633 metastatic lesion; MAPK, mitogen-activated protein kinase; MET, MET proto-oncogene; MKI, multi-
634 kinase inhibitor; MM, module membership; MS, mass spectrometry; MRI, magnetic resonance imaging;
635 NIS, sodium iodide symporter; PCA, principal component analysis; PCT, pressure cycling technology;
636 PET, positron emission tomography; RAI, radioactive iodine; RAIR, RAI-refractoriness; RF, random
637 forest; RFS, recurrence-free survival; RMA, robust multiarray average; ROC, receiver operating
638 characteristic; RR-PTC, radioactive iodine refractory papillary thyroid cancer; SPECT, single photon
639 emission computerized tomography; ssGSEA, single sample GSEA; SVM-RFE, support vector
640 machine-recursive feature elimination; TAK1, transforming growth factor- β activated kinase 1; TCGA,
641 The Cancer Genome Atlas Program; *TERT*, telomerase reverse transcriptase; *TERTp*, *TERT* promoter;
642 TDS, thyroid differentiation score; TIS, T cell infiltration score; TNF, tumor necrosis factor; TNGS,
643 targeted next-generation sequencing; TOM, topological overlap matrix; WBS, whole-body scanning;
644 WGCNA, weighted correlation network analysis.
645

646 **Disclosure**

647 Ethics approval statement

648 The Institutional Ethical Committee of the hospital reviewed and approved the study design (No.
649 WDRY2021-K032). The requirement for obtaining informed consent from the involved patients was
650 waived due to the retrospective nature of the study. The study was conducted in accordance with the
651 Declaration of Helsinki.
652

653 Acknowledgement

654 We appreciate the great support by four expert pathologists, Dr. Xiaokang Ke, Dr. Jiakai Ren, Dr.
655 Xiaoyan Wu and Dr. Feng Guan, and the secretary of the Pathology Department, Mrs. Lingli Xia, at
656 Renmin Hospital of Wuhan university. We give special thanks to Dr. Jun Liang in the Department of
657 Nuclear Medicine at Renmin Hospital of Wuhan University and Dr. Jie Tan in the Department of Breast
658 the Thyroid Surgery at Wuhan Union Hospital for their contribution and guidance in patient selection
659 and grouping. We thank Prof. Katherine Hoadley at the University of North Carolina at Chapel Hill for
660 her kind help in building a profile-based scoring system. We thank Dr. Zhou Liu from the Breast Tumor
661 Center of Sun Yat-Sen Memorial Hospital and Dr. Nancy Li from the Reactome HelpDesk for their timely
662 replies on two independent technical problems. We pay special thanks to authors who provided the
663 external expression profiles for validation in the present study.
664

665 Funding

666 This research was supported by grants from the Interdisciplinary Innovative Talents Foundation from
667 Renmin Hospital of Wuhan University (JCRCFZ-2022-015), the Fundamental Research Funds for the
668 Central Universities (2042019kf0229), the Natural Science Foundation of Hubei Province, China
669 (2023AFB701), and the Thyroid Research Project for Young and Middle-aged Doctors from Bethune
670 Charitable Foundation (JKM2022-B12). All these funds were given to Prof. Chuang Chen to cover the
671 costs during sample collection, TNGS, proteomics and other costs related to this academic research.
672

673 Conflicts of interest

674 All authors declare no competing interests.
675

676 Data and code availability

677 The proteomic data have been deposited in the iProX database with the project ID IPX0009103001.
678 Calculation files and additional data are available in the Mendeley database (DOI: 10.17632/yfpfvktrxn).
679 No custom code was used in the current study.
680

681 Author contribution

682 Conceptualization: HQ Liu (supporting) and C Chen (lead).
683 Data curation: HQ Liu, JX Wang, Y Zhou, PP Hu, L Li, DG Kong and ZL Xu (all equal).
684 Formal analysis: HQ Liu (lead), JX Wang (supporting), YT Sun (supporting) and Y Zhou (supporting).
685 Funding acquisition: C Chen (lead).
686 Investigation: HQ Liu (supporting), JX Wang (lead), D Yang (supporting), DG Kong (supporting) and
687 ZL Xu (supporting).
688 Methodology: HQ Liu (supporting), YT Sun (lead) and Y Zhou(supporting).
689 Project administration: HQ Liu, YT Sun, TN Guo and C Chen (all equal).
690 Resources: YT Sun, Y Zhu, TN Guo and C Chen (all equal).
691 Software: YT Sun (supporting), Y Zhou (lead), PP Hu (supporting) and L Li (supporting).
692 Supervision: YT Sun, Y Zhu, TN Guo and C Chen (all equal).
693 Validation: D Yang and Y Zhu (all equal).
694 Visualization: HQ Liu (supporting), D Yang (lead) and Y Zhu (supporting).
695 Writing - original draft: HQ Liu (lead), JX Wang (supporting), YT Sun (supporting) and Y Zhou
696 (supporting).
697 Writing – review & editing: D Yang (supporting), YT Sun (supporting), TN Guo (lead) and C Chen (lead).
698

699 **References**

- 700 1 Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. *CA: a cancer journal for*
701 *clinicians* **74**, 12-49, doi:10.3322/caac.21820 (2024).
- 702 2 Li, M. *et al.* Changing incidence and projections of thyroid cancer in mainland China, 1983-
703 2032: evidence from Cancer Incidence in Five Continents. *Cancer Causes & Control* **32**, 1095-
704 1105, doi:10.1007/s10552-021-01458-6 (2021).
- 705 3 Pereira, M., Williams, V. L., Johnson, J. & Valderrabano, P. Thyroid Cancer Incidence Trends
706 in the United States: Association with Changes in Professional Guideline Recommendations.
707 *Thyroid* **30**, 1132-1140, doi:10.1089/thy.2019.0415 (2020).
- 708 4 Miranda-Filho, A. *et al.* Thyroid cancer incidence trends by histology in 25 countries: a
709 population-based study. *Lancet Diabetes & Endocrinology* **9**, 225-234, doi:10.1016/s2213-
710 8587(21)00027-9 (2021).
- 711 5 Lim, H., Devesa, S. S., Sosa, J. A., Check, D. & Kitahara, C. M. Trends in Thyroid Cancer
712 Incidence and Mortality in the United States, 1974-2013. *Jama-Journal of the American*
713 *Medical Association* **317**, 1338-1348, doi:10.1001/jama.2017.2719 (2017).
- 714 6 van Velsen, E. F. S. *et al.* Evaluating Disease-specific Survival Prediction of Risk Stratification
715 and TNM Systems in Differentiated Thyroid Cancer. *Journal of Clinical Endocrinology &*
716 *Metabolism* **108**, E267-E274, doi:10.1210/clinem/dgac721 (2023).
- 717 7 Manzardo, O. A. *et al.* TNM 8th edition in thyroid cancer staging: is there an improvement in
718 predicting recurrence? *Endocrine-Related Cancer* **27**, 325-336, doi:10.1530/erc-19-0412
719 (2020).
- 720 8 Haugen, B. R. *et al.* 2015 American Thyroid Association Management Guidelines for Adult
721 Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid
722 Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
723 *Thyroid* **26**, 1-133, doi:10.1089/thy.2015.0020 (2016).
- 724 9 van Velsen, E. F. S. *et al.* Evaluating the 2015 American Thyroid Association Risk Stratification
725 System in High-Risk Papillary and Follicular Thyroid Cancer Patients. *Thyroid* **29**, 1073-1079,
726 doi:10.1089/thy.2019.0053 (2019).
- 727 10 Nunes, K. S. *et al.* Risk factors associated with disease-specific mortality in papillary thyroid
728 cancer patients with distant metastases. *Endocrine* **75**, 814-822, doi:10.1007/s12020-021-
729 02901-z (2022).
- 730 11 Durante, C. *et al.* Long-term outcome of 444 patients with distant metastases from papillary and
731 follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. *Journal of Clinical*
732 *Endocrinology & Metabolism* **91**, 2892-2899, doi:10.1210/jc.2005-2838 (2006).
- 733 12 Ciarallo, A. & Rivera, J. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020
734 Update. *American Journal of Roentgenology* **215**, 285-291, doi:10.2214/ajr.19.22626 (2020).
- 735 13 Sakulpisuti, C., Charoenphun, P. & Chamroonrat, W. Positron Emission Tomography
736 Radiopharmaceuticals in Differentiated Thyroid Cancer. *Molecules* **27**, 4936,
737 doi:10.3390/molecules27154936 (2022).
- 738 14 Durante, C. *et al.* BRAF mutations in papillary thyroid carcinomas inhibit genes involved in
739 iodine metabolism. *Journal of Clinical Endocrinology & Metabolism* **92**, 2840-2843,
740 doi:10.1210/jc.2006-2707 (2007).

- 741 15 Riesco-Eizaguirre, G. *et al.* The BRAF V600E Oncogene Induces Transforming Growth Factor
742 β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in
743 Thyroid Cancer. *Cancer Research* **69**, 8317-8325, doi:10.1158/0008-5472.Can-09-1248 (2009).
- 744 16 Liu, J. *et al.* The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly
745 Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. *Journal of Nuclear*
746 *Medicine* **61**, 177-182, doi:10.2967/jnumed.119.227652 (2020).
- 747 17 Cao, J. *et al.* The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor
748 curative effect of radioiodine therapy in papillary thyroid cancer. *European Journal of Nuclear*
749 *Medicine and Molecular Imaging* **49**, 3470-3481, doi:10.1007/s00259-022-05820-x (2022).
- 750 18 Groener, J. B. *et al.* BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary
751 Thyroid Cancer. *Hormone and Metabolic Research* **51**, 69-75, doi:10.1055/a-0765-9078 (2019).
- 752 19 Yang, X. *et al.* TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant
753 Metastatic Differentiated Thyroid Cancer. *Journal of Nuclear Medicine* **58**, 258-265,
754 doi:10.2967/jnumed.116.180240 (2017).
- 755 20 Feng, F. *et al.* A nonpump function of sodium iodide symporter in thyroid cancer via cross-talk
756 with PTEN signaling. *Cancer Research* **78**, 6121-6133, doi:10.1158/0008-5472.Can-18-1954
757 (2018).
- 758 21 Dohán, O., Baloch, Z., Bánrévi, Z., Livolsi, V. & Carrasco, N. Predominant intracellular
759 overexpression of the Na⁺/I⁻ symporter (NIS) in a large sampling of thyroid cancer cases.
760 *Journal of Clinical Endocrinology & Metabolism* **86**, 2697-2700, doi:10.1210/jc.86.6.2697
761 (2001).
- 762 22 Marsee, D. K. *et al.* Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein,
763 increases radioiodide accumulation in thyroid cells. *Journal of Biological Chemistry* **279**,
764 43990-43997, doi:10.1074/jbc.M407503200 (2004).
- 765 23 Paron, I. *et al.* Nuclear localization of Galectin-3 in transformed thyroid cells: a role in
766 transcriptional regulation. *Biochemical and Biophysical Research Communications* **302**, 545-
767 553, doi:10.1016/s0006-291x(03)00151-7 (2003).
- 768 24 Huang, D. *et al.* Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms. *Frontiers*
769 *in endocrinology* **13**, 854611, doi:10.3389/fendo.2022.854611 (2022).
- 770 25 Qu, N. *et al.* Integrated proteogenomic and metabolomic characterization of papillary thyroid
771 cancer with different recurrence risks. *Nature Communications* **15**, 3175, doi:10.1038/s41467-
772 024-47581-1 (2024).
- 773 26 Sun, Y. *et al.* Stratification of follicular thyroid tumours using data-independent acquisition
774 proteomics and a comprehensive thyroid tissue spectral library. *Molecular oncology* **16**, 1611-
775 1624, doi:10.1002/1878-0261.13198 (2022).
- 776 27 Shi, X. *et al.* Integrated proteogenomic characterization of medullary thyroid carcinoma. *Cell*
777 *discovery* **8**, 120, doi:10.1038/s41421-022-00479-y (2022).
- 778 28 Colombo, C. *et al.* The molecular and gene/miRNA expression profiles of radioiodine resistant
779 papillary thyroid cancer. *Journal of Experimental & Clinical Cancer Research* **39**, 245,
780 doi:10.1186/s13046-020-01757-x (2020).
- 781 29 Xing, M. Molecular pathogenesis and mechanisms of thyroid cancer. *Nature Reviews Cancer*
782 **13**, 184-199, doi:10.1038/nrc3431 (2013).
- 783 30 Arturi, F. *et al.* Iodide symporter gene expression in human thyroid tumors. *Journal of Clinical*
784 *Endocrinology & Metabolism* **83**, 2493-2496, doi:10.1210/jc.83.7.2493 (1998).

- 785 31 Anekpuranang, T. *et al.* The Association Between Radioiodine Refractory in Papillary Thyroid
786 Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation. *Oncotargets*
787 *and Therapy* **14**, 3959-3969, doi:10.2147/ott.S308910 (2021).
- 788 32 Zhang, R. *et al.* Association between sodium iodide symporter and differentiated Thyroid cancer:
789 a meta-analysis of 9 studies. *International Journal of Clinical and Experimental Medicine* **8**,
790 17986-17994 (2015).
- 791 33 Braga-Basaria, M. & Ringel, M. D. Beyond radioiodine: A review of potential new therapeutic
792 approaches for thyroid cancer. *Journal of Clinical Endocrinology & Metabolism* **88**, 1947-1960,
793 doi:10.1210/jc.2002-021863 (2003).
- 794 34 Agrawal, N. *et al.* Integrated Genomic Characterization of Papillary Thyroid Carcinoma. *Cell*
795 **159**, 676-690, doi:10.1016/j.cell.2014.09.050 (2014).
- 796 35 Xing, M. *et al.* Association Between BRAF V600E Mutation and Recurrence of Papillary
797 Thyroid Cancer. *Journal of Clinical Oncology* **33**, 42-U79, doi:10.1200/jco.2014.56.8253
798 (2015).
- 799 36 Luo, Y. *et al.* Clinical, Pathological, and Molecular Characteristics Correlating to the
800 Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review
801 and Meta-Analysis. *Frontiers in Oncology* **10**, 549882, doi:10.3389/fonc.2020.549882 (2020).
- 802 37 Zhang, Z., Liu, D., Murugan, A. K., Liu, Z. & Xing, M. Histone deacetylation of NIS promoter
803 underlies BRAF V600E-promoted NIS silencing in thyroid cancer. *Endocrine-Related Cancer*
804 **21**, 161-173, doi:10.1530/erc-13-0399 (2014).
- 805 38 Mu, Z. *et al.* Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic
806 Thyroid Cancer. *Journal of Clinical Endocrinology & Metabolism* **109**, 1231-1240,
807 doi:10.1210/clinem/dgad697 (2024).
- 808 39 Collina, F. *et al.* AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine
809 Refractory Thyroid Cancer. *Cancers* **11**, 785, doi:10.3390/cancers11060785 (2019).
- 810 40 Meng, Z. *et al.* TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts
811 absent or lower (131)i uptake in metastases. *Iubmb Life* **71**, 1030-1040, doi:10.1002/iub.2056
812 (2019).
- 813 41 Jung, C. K. *et al.* Risk Stratification Using a Novel Genetic Classifier Including PLEKHS1
814 Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis. *Thyroid* **30**,
815 1589-1600, doi:10.1089/thy.2019.0459 (2020).
- 816 42 Liu, R. *et al.* Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter
817 Mutations in Papillary Thyroid Cancer Genetic Duet of BRAF and TERT Promoter Mutations
818 in Thyroid Cancer Mortality. *Jama Oncology* **3**, 202-208, doi:10.1001/jamaoncol.2016.3288
819 (2017).
- 820 43 Yu, P. *et al.* TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and
821 progression by regulating ribosome biogenesis. *Science Advances* **9**, eadg7125,
822 doi:10.1126/sciadv.adg7125 (2023).
- 823 44 Ju, G. *et al.* Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic
824 Differentiated Thyroid Cancer. *Journal of Clinical Endocrinology & Metabolism* **109**, 505-515,
825 doi:10.1210/clinem/dgad500 (2024).
- 826 45 Arai, S. *et al.* In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-
827 RET. *Oncotarget* **8**, 73766-73773, doi:10.18632/oncotarget.17900 (2017).
- 828 46 Paratala, B. S. *et al.* RET rearrangements are actionable alterations in breast cancer. *Nature*

- 829 *Communications* **9**, 4821, doi:10.1038/s41467-018-07341-4 (2018).
- 830 47 Groussin, L. *et al.* Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid
831 Cancer. *Thyroid* **31**, 1603-1604, doi:10.1089/thy.2021.0144 (2021).
- 832 48 Lee, Y. A. *et al.* NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a
833 tumor response and radioiodine uptake. *Journal of Clinical Investigation* **131**, e144847,
834 doi:10.1172/jci144847 (2021).
- 835 49 Nikitski, A. V. *et al.* Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid
836 carcinoma? *Endocrine-Related Cancer* **28**, 621-630, doi:10.1530/erc-21-0095 (2021).
- 837 50 Fu, H. *et al.* MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary
838 Thyroid Cancer Cells Harboring BRAFV600E : An In Vitro. *Molecular Therapy-Oncolytics* **12**,
839 235-245, doi:10.1016/j.omto.2019.01.007 (2019).
- 840 51 Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H. & Wirth, L. J.
841 Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid
842 Cancer with Dabrafenib. *Clinical Cancer Research* **21**, 1028-1035, doi:10.1158/1078-0432.Ccr-
843 14-2915 (2015).
- 844 52 Zhang, C. *et al.* Inhibitory effects of siRNA targeting silencing TAK1 gene on proliferation and
845 migration of thyroid cancer cells and p38 MAPK signaling pathway. *Journal of Jilin Univeristy.*
846 *Medicine edition* **47**, 110-117 (2021).
- 847 53 Gheorghe, D. C., Stanciu, M. M., Zamfirescu, A. & Stanciu, A. E. TNF- α May Exert Different
848 Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer
849 with/without Autoimmune Thyroiditis. *Cancers* **13**, 3609, doi:10.3390/cancers13143609 (2021).
- 850 54 Yen, M.-C. *et al.* S100B expression in breast cancer as a predictive marker for cancer metastasis.
851 *International Journal of Oncology* **52**, 433-440, doi:10.3892/ijo.2017.4226 (2018).
- 852 55 Wang, X. *et al.* A Functional Insertion/Deletion Polymorphism in the Promoter Region of the
853 NFKB1 Gene Increases the Risk of Papillary Thyroid Carcinoma. *Genetic Testing and*
854 *Molecular Biomarkers* **19**, 167-171, doi:10.1089/gtmb.2014.0271 (2015).
- 855 56 Sponziello, M. *et al.* Fibronectin-1 expression is increased in aggressive thyroid cancer and
856 favors the migration and invasion of cancer cells. *Molecular and Cellular Endocrinology* **431**,
857 123-132, doi:10.1016/j.mce.2016.05.007 (2016).
- 858 57 Chen, X., Zheng, J., Zhang, A. & You, Z. Increased FN1 expression correlates to poor prognosis,
859 BRAF mutation and immune infiltrates in papillary thyroid cancer. *Chinese Journal of*
860 *Immunology* **37**, 1841-1847 (2021).
- 861 58 Sabra, M. M. *et al.* Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers
862 With Radioiodine-Avid Distant Metastases. *Journal of Clinical Endocrinology & Metabolism*
863 **98**, E829-E836, doi:10.1210/jc.2012-3933 (2013).
- 864 59 Shobab, L. *et al.* Clinical, Pathological, and Molecular Profiling of Radioactive Iodine
865 Refractory Differentiated Thyroid Cancer. *Thyroid* **29**, 1262-1268, doi:10.1089/thy.2019.0075
866 (2019).
- 867 60 Song, H.-J., Xue, Y.-L., Qiu, Z.-L. & Luo, Q.-Y. Comparative serum proteomic analysis
868 identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-
869 131I-avid lung metastases. *Nuclear Medicine Communications* **34**, 1196-1203,
870 doi:10.1097/mnm.0000000000000001 (2013).
- 871 61 Li, Y. *et al.* Proteomic analysis of radioiodine-refractory differentiated thyroid cancer identifies
872 CHI3L1 upregulation in association with dysfunction of the sodium-iodine symporter.

- 873 *Oncology Letters* **25**, 36, doi:10.3892/ol.2022.13622 (2023).
- 874 62 World Med, A. World Medical Association Declaration of Helsinki Ethical Principles for
875 Medical Research Involving Human Subjects. *Jama-Journal of the American Medical*
876 *Association* **310**, 2191-2194, doi:10.1001/jama.2013.281053 (2013).
- 877 63 Perrier, N. D., Brierley, J. D. & Tuttle, R. M. Differentiated and Anaplastic Thyroid Carcinoma:
878 Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging
879 Manual. *CA: a cancer journal for clinicians* **68**, 56-63, doi:10.3322/caac.21439 (2018).
- 880 64 Cai, X. *et al.* High-throughput proteomic sample preparation using pressure cycling technology.
881 *Nature Protocols* **17**, 2307-2325, doi:10.1038/s41596-022-00727-1 (2022).
- 882 65 Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural
883 networks and interference correction enable deep proteome coverage in high throughput. *Nature*
884 *Methods* **17**, 41-+, doi:10.1038/s41592-019-0638-x (2020).
- 885 66 Xiong, Y. *et al.* Application of biomarkers in the diagnosis of uncertain samples of core needle
886 biopsy of thyroid nodules. *Virchows Archiv* **479**, 961-974, doi:10.1007/s00428-021-03161-y
887 (2021).
- 888 67 Landrum, M. J. *et al.* ClinVar: public archive of interpretations of clinically relevant variants.
889 *Nucleic Acids Research* **44**, D862-D868, doi:10.1093/nar/gkv1222 (2016).
- 890 68 Tate, J. G. *et al.* COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids*
891 *Research* **47**, D941-D947, doi:10.1093/nar/gky1015 (2019).
- 892
- 893

894 **Tables, figures and supplementary materials**

895 Tables

896 Table 1. Demographic and clinicopathologic characteristic of included patients

Clinicopathological features	All patients (48)	RR-PTC (37)	Control (11)	<i>P</i> value
Age at diagnosis				
Years	38.4 ± 12.69	39.2 ± 13.29	35.6 ± 10.49	0.421
≥55 y	5 (10.4)	5 (13.5)	0 (0)	0.576
Female sex	28 (58.3)	20 (54.1)	8 (72.7)	0.319
Tumor diagnosis				
Incidental	22 (45.8)	15 (40.5)	7 (63.6)	0.302
Symptomatic	26 (54.2)	22 (59.5)	4 (36.4)	
Smoking or alcohol	9 (18.8)	8 (21.6)	1 (9.1)	0.662
BMI (kg/m ²)	24.1 ± 5.36	24.6 ± 5.75	22.5 ± 3.47	0.261
Hashimoto's thyroiditis	1 (2.1)	1 (2.7)	0 (0)	1.000
Nodular goiter	10 (20.8)	7 (18.9)	3 (27.3)	0.675
Histological subtypes^a				
cPTC	39 (81.3)	29 (78.4)	10 (90.9)	0.662
fvPTC	13 (27.1)	12 (32.4)	1 (9.1)	0.246
tcv/svPTC	6 (12.5)	5 (13.5)	1 (9.1)	1.000
Tumor size (cm)	2.1 ± 1.40	2.1 ± 1.38	2.1 ± 1.40	0.996
Multifocality	36 (75.0)	28 (75.7)	8 (72.7)	1.000
Bilateral lesion	27 (56.3)	20 (54.1)	7 (63.6)	0.733
ETE	37 (77.1)	31 (83.8)	6 (54.5)	0.095
TNM				
T1	7 (14.6)	3 (8.1)	4 (36.4)	0.039 *
T2-4	41 (85.4)	34 (91.9)	7 (63.6)	
N0	3 (6.3)	3 (8.1)	0 (0)	1.000
N1	45 (93.8)	34 (91.9)	11 (100)	0.006 **
M0	26 (54.2)	16 (43.2)	10 (90.9)	
M1	22 (45.8)	21 (56.8)	1 (9.1)	0.001 **
AJCC stage				
I	22 (45.8)	12 (32.4)	10 (90.9)	0.001 **
II/III/IV	26 (54.2)	25 (67.6)	1 (9.1)	
ATA risk stratification				
Low	0 (0)	0 (0)	0 (0)	1.000
Intermediate/high	48 (100)	37 (100)	11 (100)	
Cumulative dose of RAI (mCi)	370 (220, 570)	430 (220, 430)	220 (220, 250)	0.002 **
Follow up				0.313

Alive	42 (87.5)	31 (83.8)	11 (100)
Dead	6 (12.5)	6 (16.2)	0 (0)

897 Note: Quantitative variables were displayed as mean \pm standard deviation, whereas qualitative variables
898 were displayed as number (ratio). The cumulative dose of RAI was presented as medians (quartiles) due
899 to inconformity to Gaussian distribution.

900 ^a Multiple tumors in one patient may exhibit different histopathological types. The diameters of the
901 largest tumor were measured when multiple lesions existed.

902 * $P < 0.05$, ** $P < 0.01$.

903 Abbreviations: AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; BMI,
904 body mass index; cPTC, classic papillary thyroid cancer; ETE, extrathyroidal extension; fvPTC,
905 follicular variant of papillary thyroid cancer; RAI, radioactive iodine; svPTC, solid variant of papillary
906 thyroid cancer; tcvPTC, tall cell variant of papillary thyroid cancer.

907

908

Table 2. The comparison of gene mutations and fusions in RAI-refractory and RAI-sensitive PTC

Comparison	BRAF	RET	TERTp	TP53	Fusion ^a	RET fusion	NCOA4-RET
RR-PTC vs. Control							
RR-PTC (35)	19 (54.3)	0 (0)	6 (17.1)	1 (2.9)	10 (28.6)	8 (22.9)	7 (20.0)
Control (10)	6 (60.0)	1 (10.0)	0 (0)	1 (10.0)	4 (40.0)	2 (20.0)	1 (10.0)
<i>P</i> value	1.000	0.222	0.312	0.399	0.700	1.000	0.661
Subgroups							
ID (9)	1 (11.1) *	0 (0)	1 (11.1)	1 (11.1)	4 (44.4)	4 (44.4)	4 (44.4) *
iDF (9)	6 (66.7)	0 (0)	3 (33.3) *	0 (0)	1 (11.1)	1 (11.1)	0 (0)
iDG (17)	12 (70.6)	0 (0)	2 (11.8)	0 (0)	5 (29.4)	3 (17.6)	3 (17.6)
Id (10)	6 (60.0)	1 (10.0)	0 (0)	1 (10.0)	4 (40.0)	2 (20.0)	1 (10.0)
<i>P</i> value	0.026 *	0.311	0.193	0.411	0.421	0.327	0.081
I-131 uptake							
Negative (26)	18 (69.2)	0 (0)	5 (19.2)	0 (0)	6 (23.1)	4 (15.4)	3 (11.5)
Positive (19)	7 (36.8)	1 (5.3)	1 (5.3)	2 (10.5)	8 (42.1)	6 (31.6)	5 (26.3)
<i>P</i> value	0.039 *	0.422	0.222	0.173	0.206	0.281	0.253

909

* $P < 0.05$. Bold font indicated statistical significance revealed by z test.







910

^a Detected gene fusions included *ETV6-NTRK3* in three samples, one *STRN-ALK*, two *CCDC6-RET* and

911


eight *NCOA4-RET*. The latter two fusions were collectively called *RET* fusion.

912



915 Figure 1. Proteomic overview of RAI-refractory and RAI-sensitive PTC samples. (A-C) Dimension reduction visualization of the analyzed PTC samples. The samples were labeled according to
916 their response to I-131 treatment (refractory or sensitive), subgroup (iDF, iDG, ID or Id) and *BRAF* mutation status. Three samples whose quality control for sequencing failed were not included
917 in Figure C. (D) Differential expression analysis of samples in the RR-PTC and control groups. Unadjusted *P* values < 0.05 and absolute FC > 1.414 were defined as thresholds for DEPs. (E)
918 Overview of the proteomic profiles. *Z* scores of the DEPs were calculated. (F) Correlation of scores and groups. Error bar denoted 95% CI. The TDS was lower in the RR-PTC group ($-0.17 \pm$
919 0.562 vs. 0.03 ± 0.512 , $P = 0.288$). Conversely, the ERK score was greater in the RR-PTC group (0.03 ± 0.317 vs. -0.10 ± 0.297 , $P = 0.215$). The means and SDs are presented with boxes and
920 error bars.

921 Abbreviations: age at D, age at diagnosis; DM, distant metastasis; ETE, extrathyroidal extension; LNM, lymph node metastasis.




922

923

924

Figure 2. Differential expression analysis of the ID and iDF groups. (A) PCA plot of the two groups. (B) Differential expression analysis of samples in the two groups. Unadjusted P values < 0.05 and absolute FC > 1.414 were defined as thresholds for DEPs. (C) Correlations of scores and groups. Error bar denoted 95% CI. The TDS was greater in the ID group (0.03 ± 0.599 vs. -

925 $0.20 \pm 0.454, P = 0.356$), while the ERK score was greater in the iDF group (-0.07 ± 0.345 vs. $0.07 \pm 0.300, P = 0.386$). (D) Expression profiles of 145 DEPs. (E&F) GSEA based on the KEGG
926 and Reactome databases. Sixteen pathways are presented in the plot.
927




928
929
930
931
932
933

Figure 3. Expression of selected genes according to the enriched pathways identified in the ID vs. iDF and ID vs. Id comparisons. (A&D) Dysregulated pathways identified in the ID vs. iDF and ID vs. Id comparisons. The P value threshold was 0.05. No threshold was set for fold change. (B) The ten most significantly enriched pathways and the thirteen selected pathways. (C) The selected proteins from the thirteen selected pathways. The threshold of absolute fold change was > 1.2 . (E) The eight significantly enriched pathways and thirteen selected pathways. (F) The selected proteins from the thirteen selected pathways. The TNF signaling pathway and the TAK1-related pathways were combined in a single plot since the proteins strongly overlapped.

* $P < 0.05$, ** $P < 0.01$.

934 ^a The pathway “MET activates PTPN1” was also selected for subsequent identification of proteins.
935 ^{b, c} Involved in the selected pathways “glutathione synthesis and recycling” and “MET activates PTPN11”, respectively.
936 ^d Both CDK1 and MAP2K1 participate in the pathways “MAPK3 (ERK1) activation” and “RAF-independent MAPK1/3 activation”, and MAP2K1 is also a participant in “prolonged ERK
937 activation events”.
938 ^e TAB2 and TAB1 are involved in both MAPK and TAK1-associated pathways, while CD14 participates in TAK1-associated pathways.
939 ^f Molecules in these figures might participate in several pathways. The associations of molecules and pathways are provided in Sup table S5.







940

941




942

Figure 4. Differential expression analysis of the ID and Id groups. (A) PCA plot of the two groups. (B) Differential expression analysis of samples in the two groups. Unadjusted P values < 0.05 and absolute FC > 1.414 were defined as thresholds for DEPs. (C) Correlations of scores and groups. Error bar denoted 95% CI. No significant difference was found in the TDS (0.03 ± 0.599)

943 vs. 0.03 ± 0.512 , $P = 0.985$) or ERK score (-0.07 ± 0.345 vs. -0.10 ± 0.297 , $P = 0.796$). (D) Expression profiles of 125 DEPs. (E&F) GSEA based on the KEGG and Reactome databases. Sixteen
944 pathways are presented in the plot.



946 Figure 5. Gene variants and weighted gene co-expression network analysis. (A) Gene variance landscape. (B) Correlations of gene modules and gene phenotypes. The cells were divided into
947 upper left (correlation coefficient) and lower right (*P* value) parts. (C) The intersection of LASSO-, RF- and SVM-RFE-identified biomarkers for *BRAF*, and *TERTp* mutations, gene fusions and
948 *NCOA4-RET* fusion. (D) Validation of six genes in the TCGA-THCA cohort and merged GEO cohort. *PTCD1* was not detected in the merged GEO dataset.
949 ^a The low number of *TERTp*-positive samples (*n* = 6) prevented model construction and error analysis for *TERTp* mutations via the SVM algorithm. The first ten proteins with the top average
950 rank were processed for biomarker identification.



952 Figure 6. (A) Flow chart of patient and sample selection. Strict criteria were followed to identify patients with RAI-refractory or RAI-sensitive thyroid cancers. Individuals with insufficient
953 radiological evidence were also excluded from the second round of selection. A total of 73 patients (in the dashed box) were revealed to have regional or distant metastatic lesions with solid
954 evidence. The FFPE tissues were collected for subsequent proteomic analysis and/or targeted deep sequencing. Notably, 25 patients were excluded from this study due to a lack of primary lesions
955 or not having PTC. (B) Grouping of included patients. Three samples are shown here for the Id, ID and iD groups. The first patient belonged to the Id group. Her or his lung metastases, which
956 were confirmed by I-131 WBS and chest CT, were eliminated by two I-131 treatments. The second patient was included in the ID group. She or he received total thyroidectomy but her or his
957 cervical regional metastatic lesion progressed during the four rounds of I-131 treatment. The first and second I-131 WBSs of the third patient revealed no positive focus. However, PET/CT during
958 the same period revealed several suspicious pulmonary nodules (red arrow), which were confirmed to be metastases by subsequent surgery and histopathology. (C) Information on the collected
959 FFPE samples. The protein profiles of 168 samples were evaluated in 10 batches. The sample types included primary lesions, synchronous and post I-131 cervical LNM, negative cervical lymph
960 node and regional or distant metastatic lesions. Notably, the regional metastatic lesions were tumors near the primary site, such as the esophagus, trachea and cervical skin. LNM was not included
961 in regional metastatic lesions. In addition, forty-eight primary tumors were examined via targeted deep sequencing.

962 ^a The primary lesion of one patient was neither resected in our center nor examined to be PTC.

963

964	Supplementary materials
965	Supplementary methods
966	Supplementary tables 1-7
967	Supplementary figure 1-12
968	References
969	